Aurobindo Pharma, Ltd. v. Azurity Pharmaceuticals Inc.
Infringement action filed 12 Mar 2026 in the United States District Court for the District of Delaware and closed 7 Apr 2026, with US8795725B2 asserted. Recorded basis of termination: voluntary dismissal.
Case record
- Patent involved
- US8795725B2
- Application no.
- US11/269045
- Case no.
- 1:26-cv-00265
- Verdict cause
- Infringement action
- Court
- D. Del.
- Court level
- District Court
- Case region
- Delaware
- Chief judge
- Maryellen Noreika
- Trial level
- First instance
- Filed – Closed
- 12 Mar 2026 – 7 Apr 2026
- Duration
- 26 days
- Basis of termination
- Voluntary dismissal
- Products & marks
- GABA analog prodrug sustained release oral dosage forms
- Validity challenges
- None recorded
Check this patent against your own product
Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.
Get an FTO claim chart- 01Ranked prior artEvery hit source-linked
- 02Claim-level comparisonAgainst your own product
- 03Legal statusAcross 174 jurisdictions
GABA analog prodrug sustained release oral dosage forms
Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
- Legal status
- Active
- Granted
- 5 Aug 2014
- Earliest priority
- 4 Nov 2004
- Est. expiry
- 10 Jun 2029
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Inventors
- CUNDY, KENNETH C. · SASTRY, SRIKONDA · LEUNG, MANSHIU · KADRI, BALAJI V. · STACH, PAUL E.
- Classification
- A61K9/22
- Prosecution counsel
- Polsinelli PC
- Examiner
- LOVE, TREVOR
Parties of record
Aurobindo Pharma, Ltd.
- Core tech
- Not recorded
- Counsel
- Stamatios Stamoulis
- Firm
- Stamoulis & Weinblatt LLC
Azurity Pharmaceuticals Inc.
- Core tech
- Not recorded
- Counsel
- Bindu Ann George Palapura
- Firm
- Potter, Anderson & Corroon LLP
Counsel of record
| Attorney | For | Role |
|---|---|---|
| Stamatios Stamoulis | Aurobindo Pharma, Ltd. | Plaintiff |
| Bindu Ann George Palapura | Azurity Pharmaceuticals Inc. | Defendant |
Basis of termination
From the record · verbatim“Plaintiff Aurobindo Pharma Ltd. hereby files this Notice of Voluntary Dismissal of its complaint against all defendants in the above captioned matter pursuant to Federal Rule of Civil Procedure 41(a)(1). According to Rule 41(a)(1), a party may be dismissed from an action by Plaintiff without order of court by filing a notice of dismissal at any time before service of an answer by the adverse party to be dismissed. No defendant has filed an answer or other response to the Complaint to date. The Plaintiff hereby voluntarily dismisses its Complaint against all defendants without prejudice pursuant to Rule 41(a)(1).”
Case 1:26-cv-00265 · D. Del. · closed 7 April 2026
Related cases
Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.
Frequently asked questions
What is case 1:26-cv-00265?
1:26-cv-00265 is a patent infringement action brought by Aurobindo Pharma, Ltd. against Azurity Pharmaceuticals Inc., filed on 12 Mar 2026 in the United States District Court for the District of Delaware. The case closed on 7 April 2026.
Which patent was asserted in 1:26-cv-00265?
US8795725B2 (“GABA analog prodrug sustained release oral dosage forms”), assigned to XENOPORT, INC., currently active. The record also lists GABA analog prodrug sustained release oral dosage forms.
How was case 1:26-cv-00265 terminated?
The recorded basis of termination is voluntary dismissal. The termination text reads: “Plaintiff Aurobindo Pharma Ltd. hereby files this Notice of Voluntary Dismissal of its complaint against all defendants in the above captioned matter pursuant to Federal Rule of Civil Procedure 41(a)(1). According to Rule 41(a)(1), a party may be dismissed from an action by Plaintiff without order of court by filing a notice of dismissal at any time before service of an answer by the adverse party to be dismissed. No defendant has filed an answer or other response to the Complaint to date. The Plaintiff hereby voluntarily dismisses its Complaint against all defendants without prejudice pursua
What does dismissal without prejudice mean?
A dismissal without prejudice ends this action but leaves the claims alive — the plaintiff may file them again later, subject to the limitation period.
How long did case 1:26-cv-00265 take?
26 calendar days, from filing on 12 Mar 2026 to closure on 7 April 2026.
Who were the attorneys and the judge in 1:26-cv-00265?
Chief Judge Maryellen Noreika presided. Stamatios Stamoulis is recorded as counsel for plaintiff Aurobindo Pharma. Bindu Ann George Palapura appears for defendant Azurity Pharmaceuticals.
Disclaimer. This page reproduces publicly available court docket data for case 1:26-cv-00265 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.
No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.
No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.